NCT07008638 Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
| NCT ID | NCT07008638 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Condition | Acute Myeloid Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 32 participants in total. It began in 2025-07-07 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML). The primary endpoint of the study is to define safety/tolerability (phase I) and preliminary efficacy profile (phase II) of the treatment. The secondary endpoints of interest are complete remission (CR) rate, detectable minimal residual disease (MRD) status, overall response rate (ORR), rate of allogeneic hematopoietic cell transplantation (allo-HCT), treatment-related mortality (TRM), overall survival (OS), achievement of complete remission anytime in 1 year, and disease-free survival (DFS) at 1 year and 2 years. All the patient outcomes assessments will be performed as part of standard-of-care AML management. The hypothesis is the combination of bortezomib and CPX-351 will have an acceptable safety profile in this patient population based on the data from previous studies. The treatment will attenuate Nuclear Factor kB pathway activation in these cells and eradicate TP53m leukemia stem cells (LSC) leading to increased response rate and survival in these patients.
Eligibility Criteria
Inclusion Criteria: * Adult (age ≥ 18 years at time of consent) * Have not received any systemic chemotherapy for the treatment of AML. Use of hydroxyurea and leukapheresis to control excess peripheral blasts is permissible. WBC \< 25,000 to initiate bortezomib, must reach this threshold by day 7 of CPX-351. * Karnofsky performance status (KPS) ≥ 70 * Adequate renal, hepatic and cardiac function defined as * Renal: An estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2 * Hepatic: AST and ALT ≤3 x ULN, ALP ≤2.5 x ULN, and total bilirubin ≤1.5 x ULN. (exception for Gilbert's syndrome or leukemic infiltration of liver) * Cardiac: New York Heart Association (NYHA) Class I or II, left ventricular ejection fraction \> 50% by echocardiogram, MUGA or cardiac MRI * Sexually active couples of childbearing potential must agree to use effective contraception or abstinence during treatment and for at least 7 months after the final dose of study drug * Provides voluntary written consent before the performance of any study related activities not part of standard of care. Exclusion Criteria: * Received systemic chemotherapy for the treatment of AML * Bi-phenotypic acute leukemia or mixed lineage leukemia, acute promyelocytic leukemia * Active central nervous system malignancy or symptoms of CNS involvement * Symptomatic extramedullary disease * Known history of uncontrolled HIV or active hepatitis B or active hepatitis C infection * Has any of the following cardiac abnormalities * Symptomatic congestive heart failure * Myocardial infarction less than or equal to 6 months prior to enrollment * Unstable angina pectoris * Serious uncontrolled cardiac arrhythmia * Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Potential participants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g., cervix) may enroll irrespective of the time of diagnosis * Participants for whom administration of CPX-351 would exceed their lifetime cumulative daunorubicin exposure limit of 550 mg/m2 (or 400 mg/m2 in patients with prior chest radiation) or equivalent anthracycline dose. * Pregnant or breastfeeding, or planning pregnancy within 3 months after the treatment completion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07008638 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07008638 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07008638 currently recruiting?
Yes, NCT07008638 is actively recruiting participants. Contact the research team at norto491@umn.edu for enrollment information.
Where is the NCT07008638 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07008638 clinical trial?
NCT07008638 is sponsored by Masonic Cancer Center, University of Minnesota. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.